BioCentury
ARTICLE | Clinical News

Xience V: Post-marketing study data

June 7, 2010 7:00 AM UTC

In the international SPIRIT V Diabetes trial in 324 patients with diabetes, Xience V was superior to Taxus Liberte on the primary endpoint of in-stent late loss at 9 months (0.19 vs. 0.39 mm, p=0.0001). There was no significant difference between Xience V and Taxus on the composite endpoint of cardiac death, target vessel myocardial infarction and ischemia-driven TLR (11.2% vs. 12.5%, p=0.71). Abbott said the study was not powered for significance on any of the clinical endpoints. Data were presented at the EuroPCR meeting in Paris. ...